​

AbbVie (ABBV) Stock Forecast, Price Target & Predictions

OverviewRevenueOwnershipFinancialsChartTranscripts

ABBV Stock Forecast

AbbVie (ABBV) stock forecast, based on 39 Wall Street analysts, predicts a 12-month average price target of $260.29, with a high of $289.00 and a low of $242.00. This represents a 16.26% increase from the last price of $223.89.

$150 $180 $210 $240 $270 $300 High: $289 Avg: $260.29 Low: $242 Last Closed Price: $223.89

ABBV Stock Rating

AbbVie stock's rating consensus is Buy, based on 39 Wall Street analysts. The breakdown includes 0 Strong Buy (0.00%), 26 Buy (66.67%), 12 Hold (30.77%), 1 Sell (2.56%), and 0 Strong Sell (0.00%).

Buy
Total 39 1 12 26 Strong Sell Sell Hold Buy Strong Buy

ABBV Price Target Upside V Benchmarks

TypeNameUpside
StockAbbVie16.26%
SectorHealthcare Stocks 15.45%
IndustryDrug Manufacturers - General Stocks7.11%

Price Target Trends

1M3M12M
# Anlaysts21113
Avg Price Target$267.00$256.91$250.85
Last Closing Price$223.89$223.89$223.89
Upside/Downside19.25%14.75%12.04%
Ratings Trends
DateStrong BuyBuyHoldSellStrong SellTotal
Dec, 257139-130
Nov, 255139-128
Oct, 255148-128
Sep, 2551310--28
Aug, 2531311--27
Analyst Price Target Forecasts
DateAnalystCompanyPrice TargetPrice when PublishedPrice Target/Price when PublishedPrice Target/Last Closing Price
Dec 12, 2025Morgan Stanley$269.00$222.4820.91%20.15%
Dec 10, 2025HSBC$265.00$222.9918.84%18.36%
Nov 05, 2025David AmsellemPiper Sandler$289.00$213.5735.32%29.08%
Nov 03, 2025Gary NachmanRaymond James$256.00$218.0417.41%14.34%
Oct 20, 2025Guggenheim$242.00$229.575.41%8.09%
Oct 17, 2025Gary NachmanRaymond James$250.00$226.8710.20%11.66%
Oct 10, 2025Piper Sandler$284.00$230.6923.11%26.85%
Oct 09, 2025Cantor Fitzgerald$250.00$231.248.11%11.66%
Oct 03, 2025UBS$251.00$236.566.10%12.11%
Oct 02, 2025HSBC$225.00$244.38-7.93%0.50%
Analyst Rating Forecasts
DateCompanyPrevious RatingNew RatingRating Change
Dec 12, 2025Morgan StanleyOverweightOverweighthold
Dec 10, 2025HSBCHoldBuyupgrade
Nov 05, 2025Piper SandlerOverweightOverweighthold
Nov 03, 2025CitigroupNeutralNeutralhold
Oct 20, 2025GuggenheimBuyBuyhold
Oct 17, 2025Raymond JamesOutperformOutperformhold
Oct 13, 2025CitigroupNeutralNeutralhold
Oct 10, 2025Piper SandlerOverweightOverweighthold
Oct 09, 2025Cantor FitzgeraldOverweightOverweighthold
Oct 01, 2025HSBCBuyHolddowngrade

Financial Forecast

EPS Forecast

$0 $4 $8 $12 $16 $20 Dec 20 Dec 21 Dec 22 Dec 23 Dec 24 Dec 25 Dec 26 Dec 27 Dec 28
Dec 20Dec 21Dec 22Dec 23Dec 24Dec 25Dec 26Dec 27Dec 28
Reported$2.73$6.48$6.65$2.73$2.42----
Avg Forecast$10.48$12.68$13.76$11.13$10.94$12.19$13.70$15.05$16.61
High Forecast$10.69$12.93$14.12$11.24$11.61$12.77$18.63$18.63$16.97
Low Forecast$10.28$12.43$13.34$11.08$10.67$11.57$7.28$7.23$15.93
Surprise %-73.95%-48.90%-51.67%-75.47%-77.88%----

Revenue Forecast

$40B $47B $54B $61B $68B $75B Dec 20 Dec 21 Dec 22 Dec 23 Dec 24 Dec 25 Dec 26 Dec 27 Dec 28
Dec 20Dec 21Dec 22Dec 23Dec 24Dec 25Dec 26Dec 27Dec 28
Reported$45.80B$56.20B$58.05B$54.32B-----
Avg Forecast$45.64B$56.23B$58.27B$54.05B$56.04B$59.15B$63.51B$67.43B$71.61B
High Forecast$46.34B$57.10B$59.43B$54.35B$56.19B$59.78B$63.52B$67.44B$72.82B
Low Forecast$44.96B$55.40B$56.89B$53.94B$55.94B$58.25B$63.49B$67.41B$69.37B
Surprise %0.37%-0.07%-0.37%0.50%-----

Net Income Forecast

$0 $7B $14B $21B $28B $35B Dec 20 Dec 21 Dec 22 Dec 23 Dec 24 Dec 25 Dec 26 Dec 27 Dec 28
Dec 20Dec 21Dec 22Dec 23Dec 24Dec 25Dec 26Dec 27Dec 28
Reported$4.62B$11.54B$11.84B$4.86B$4.28B----
Avg Forecast$4.39B$11.26B$13.10B$4.82B$19.75B$21.58B$14.78B$19.27B$29.44B
High Forecast$5.54B$13.51B$15.72B$5.78B$20.59B$22.64B$33.03B$33.02B$30.08B
Low Forecast$3.24B$9.01B$10.48B$3.86B$18.91B$20.51B$12.90B$12.83B$28.24B
Surprise %5.19%2.52%-9.67%0.89%-78.34%----

ABBV Forecast FAQ

Is AbbVie stock a buy?

AbbVie stock has a consensus rating of Buy, based on 39 Wall Street analysts. The rating breakdown includes 0 Strong Buy, 26 Buy, 12 Hold, 1 Sell, and 0 Strong Sell, reflecting a consensus that AbbVie is a favorable investment for most analysts.

What is AbbVie's price target?

AbbVie's price target, set by 39 Wall Street analysts, averages $260.29 over the next 12 months. The price target range spans from $242 at the low end to $289 at the high end, suggesting a potential 16.26% change from the previous closing price of $223.89.

How does AbbVie stock forecast compare to its benchmarks?

AbbVie's stock forecast shows a 16.26% upside, outperforming the average forecast for the healthcare stocks sector (15.45%) and outperforming the drug manufacturers - general stocks industry (7.11%).

What is the breakdown of analyst ratings for AbbVie over the past three months?

  • December 2025: 23.33% Strong Buy, 43.33% Buy, 30.00% Hold, 0% Sell, 3.33% Strong Sell.
  • November 2025: 17.86% Strong Buy, 46.43% Buy, 32.14% Hold, 0% Sell, 3.57% Strong Sell.
  • October 2025: 17.86% Strong Buy, 50.00% Buy, 28.57% Hold, 0% Sell, 3.57% Strong Sell.

What is AbbVie’s EPS forecast?

AbbVie's average annual EPS forecast for its fiscal year ending in December 2025 is $12.19, marking a 403.72% increase from the reported $2.42 in 2024. Estimates for the following years are $13.7 in 2026, $15.05 in 2027, and $16.61 in 2028.

What is AbbVie’s revenue forecast?

AbbVie's average annual revenue forecast for its fiscal year ending in December 2025 is $59.15B, reflecting a 0% decrease from the reported $0 in 2024. The forecast for 2026 is $63.51B, followed by $67.43B for 2027, and $71.61B for 2028.

What is AbbVie’s net income forecast?

AbbVie's net income forecast for the fiscal year ending in December 2025 stands at $21.58B, representing an 404.34% increase from the reported $4.28B in 2024. Projections indicate $14.78B in 2026, $19.27B in 2027, and $29.44B in 2028.